Psoriatic Arthritis

Conference Coverage

Joseph Merola, MD, MMSc, on the Long-Term Efficacy of Risankizumab for PsA

07/19/2023

Dr Merola and colleagues conducted a post hoc analysis of the KEEPsAkE 1 and 2 trials of risankizumab among patients with active psoriatic arthritis to evaluates patient subgroups at 52 weeks of treatment.

Dr Merola and colleagues...

07/19/2023

Rheumatology & Arthritis

Conference Coverage

Alexis Ogdie, MD, on Clinical Measures and PROs in PsA

03/17/2023

Dr Ogdie, from the University of Pennsylvania, discusses the analysis of results from the KEEPsAKE trials of risankizumab regarding the association of clinical measures and patient-reported outcomes in psoriatic arthritis.

Dr Ogdie, from the University of...

03/17/2023

Rheumatology & Arthritis

Conference Coverage

Laura Coates, MBBS, on Upadacitinib Vs Adalimumab on RAPID3 Among Patients With Psoriatic Arthritis

02/22/2023

Dr Coates presented a poster at ACR Convergence examining the efficacy of upadacitinib vs adalimumab in treating psoriatic arthritis, using the RAPID3 tool to assess disease activity.

Dr Coates presented a poster at...

02/22/2023

Rheumatology & Arthritis

Conference Coverage

Alexis Ogdie, MD, on PEST Screening Among Patients With PsO

02/13/2023

Rebecca Mashaw ;

Dr Ogdie, from the University of Pennsylvania, presented an abstract at ACR Convergence 2022 on research she and colleagues conducted highlighting the need to actively screen patients with psoriasis for their risk of developing psoriatic...

Dr Ogdie, from the University of...

02/13/2023

Rheumatology & Arthritis

Conference Coverage

Alexis Ogdie, MD, on Response Rates in PsA: Results from the KEEPsAKE Trials of Risankizumab

11/14/2022

Dr Ogdie, from the University of Pennsylvania, reviews her poster presentation from ACR Convergence 2022 on response rates among patients treated with risankizumab based on the number of swollen and tender joints, from the KEEPsAKE 1 and 2...

Dr Ogdie, from the University of...

11/14/2022

Rheumatology & Arthritis

Conference Coverage

Fatigue Drives Health Care Costs in PsA

07/22/2022

A study presented at ACR Convergence 2021 shows that patients with psoriatic arthritis who also suffer from fatigue incurred higher resource use and health care costs than those without fatigue.

A study presented at ACR...

07/22/2022

Rheumatology & Arthritis

Conference Coverage

PsA Carries Risk of Vertebral Fracture

02/18/2022

A new study demonstrates that patients with psoriatic arthritis, as in other inflammatory diseases, are at higher risk of fractures in the vertebrae.

A new study demonstrates that...

02/18/2022

Rheumatology & Arthritis

Podcast

Alexis Ogdie, MD, on Depression Among Patients with PsA and Active PsO

02/03/2022

In this podcast, Dr Ogdie discusses her research into the relationship between depression and active psoriasis and psoriatic arthritis, presented at the recent ACR Convergence meeting.

In this podcast, Dr Ogdie...

02/03/2022

Rheumatology & Arthritis

Podcast

Ana-Maria Orbai, MD, on Validating the PROMIS 29 Profile for PsA

01/31/2022

Dr Orbai, from Johns Hopkins University, discusses her project to validate the PROMIS 29 profile for use in assessing several disease domains among patients with psoriatic arthritis, which she spoke about at ACR Convergence 2021.

Dr Orbai, from Johns Hopkins...

01/31/2022

Rheumatology & Arthritis

Podcast

Ana-Maria Orbai, MD, on the DISCOVER 1 Trial of Guselkumab for Psoriatic Arthritis

12/07/2021

Dr Orbai, from Johns Hopkins University, recaps a presentation on the findings of a trial of guselkumab for the treatment of psoriatic arthritis at ACR Convergence 2021.

Dr Orbai, from Johns Hopkins...

12/07/2021

Rheumatology & Arthritis